An HIV-1 Envelope Glycoprotein Trimer with an Embedded IL-21 Domain Activates Human B Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Isik, Gözde ^a   Chung, Nancy P Y ^b   van Montfort, Thijs ^a   Menis, Sergey ^c,d   Matthews, Katie ^b   Schief, William R ^d   Moore, John P ^b   Sanders, Rogier W ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD40 LIGAND; CHIMERIC PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 21 VIRUS ENVELOPE PROTEIN FUSION PROTEIN; INTERLEUKIN 4 VIRUS ENVELOPE PROTEIN FUSION PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING;

ANTIGENS, VIRAL; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV-1; HUMANS; INTERLEUKINS; LYMPHOCYTE ACTIVATION; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84879492157     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067309     Document Type: Article

References (88)

1. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286 10.1056/NEJMoa1113425 [doi].
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220 NEJMoa0908492 [pii];10.1056/NEJMoa0908492 [doi].
3. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6: 200-206 10.1038/72309 [doi].
4. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, et al. (2011) Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 108: 11181-11186 1103012108 [pii];10.1073/pnas.1103012108 [doi].
5. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009-4018.
6. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210 10.1038/72318 [doi].
7. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347.
8. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, et al. (1999) Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5: 204-210 10.1038/5568 [doi].
9. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, et al. (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9: 343-346 10.1038/nm833 [doi];nm833 [pii].
10. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, et al. (2001) The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75: 5526-5540 10.1128/JVI.75.12.5526-5540.2001 [doi].
11. Bontjer I, Melchers M, Eggink D, David K, Moore JP, et al. (2010) Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. J Biol Chem 285: 36456-36470 M110.156588 [pii];10.1074/jbc.M110.156588 [doi].
12. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236 10.1038/ni0304-233 [doi];ni0304-233 [pii].
13. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, et al. (1997) Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 71: 9808-9812.
14. Kwong PD, Wilson IA, (2009) HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10: 573-578 ni.1746 [pii];10.1038/ni.1746 [doi].
15. Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L, (2003) Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 77: 2310-2320.
16. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343 nature10696 [pii];10.1038/nature10696 [doi].
17. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, et al. (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334: 1097-1103 science.1213256 [pii];10.1126/science.1213256 [doi].
18. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, et al. (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76: 7293-7305.
19. Scanlan CN, Pantophlet R, Wormald MR, Ollmann SE, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 76: 7306-7321.
20. Reitter JN, Means RE, Desrosiers RC, (1998) A role for carbohydrates in immune evasion in AIDS. Nat Med 4: 679-684.
21. Reitter JN, Desrosiers RC, (1998) Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. J Virol 72: 5399-5407.
22. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312 10.1038/nature01470 [doi];nature01470 [pii].
23. Crooks ET, Tong T, Osawa K, Binley JM, (2011) Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol 85: 5825-5839 JVI.00154-11 [pii];10.1128/JVI.00154-11 [doi].
24. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, et al. (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80: 2515-2528 80/5/2515 [pii];10.1128/JVI.80.5.2515-2528.2006 [doi].
25. Parren PW, Burton DR, Sattentau QJ, (1997) HIV-1 antibody-debris or virion? Nat Med 3: 366-367.
26. Parren PW, Burton DR, (1997) Antibodies against HIV-1 from phage display libraries: mapping of an immune response and progress towards antiviral immunotherapy. Chem Immunol 65: 18-56.
27. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, et al. (2000) A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74: 627-643.
28. Dey AK, David KB, Lu M, Moore JP, (2009) Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 385: 275-281 S0042-6822(08)00802-7 [pii];10.1016/j.virol.2008.12.009 [doi].
29. Li Y, O'Dell S, Wilson R, Wu X, Schmidt SD, et al. (2012) HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J Virol 86: 11231-11241 JVI.01543-12 [pii];10.1128/JVI.01543-12 [doi].
30. Pancera M, Wyatt R, (2005) Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332: 145-156 S0042-6822(04)00727-5 [pii];10.1016/j.virol.2004.10.042 [doi].
31. Si Z, Phan N, Kiprilov E, Sodroski J, (2003) Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res Hum Retroviruses 19: 217-226 10.1089/088922203763315722 [doi].
32. Anderson KP, Lucas C, Hanson CV, Londe HF, Izu A, et al. (1989) Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1. J Infect Dis 160: 960-969.
33. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191: 666-677 JID33334 [pii];10.1086/428405 [doi].
34. Banerjee K, Michael E, Eggink D, van Montfort T, Lasnik AB, et al. (2012) Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS Res Hum Retroviruses 28: 206-214 10.1089/aid.2011.0101 [doi].
35. Chung NP, Matthews K, Klasse PJ, Sanders RW, Moore JP (2012) HIV-1 gp120 Impairs the Induction of B Cell Responses by TLR9-Activated Plasmacytoid Dendritic Cells. J Immunol. jimmunol.1201905 [pii];10.4049/jimmunol.1201905 [doi].
36. Martinelli E, Cicala C, Van Ryk D, Goode DJ, Macleod K, et al. (2007) HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 104: 3396-3401 0611353104 [pii];10.1073/pnas.0611353104 [doi].
37. Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SP, et al. (2007) HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog 3: e169 07-PLPA-RA-0438 [pii];10.1371/journal.ppat.0030169 [doi].
38. Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, et al. (2009) Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology 389: 108-121 S0042-6822(09)00236-0 [pii];10.1016/j.virol.2009.04.001 [doi].
39. Kutzler MA, Weiner DB, (2004) Developing DNA vaccines that call to dendritic cells. J Clin Invest 114: 1241-1244 10.1172/JCI23467 [doi].
40. Yu H, Tawab-Amiri A, Dzutsev A, Sabatino M, Aleman K, et al. (2011) IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses. J Leukoc Biol 90: 205-214 jlb.1010579 [pii];10.1189/jlb.1010579 [doi].
41. Isik G, van Montfort T, Boot M, Cobos Jiménez V, Kootstra NA, et al. (2013) Chimeric HIV-1 Envelope Glycoproteins with Potent Intrinsic Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Activity. PLoS One 8: e60126 doi:10.1371.
42. van Montfort T, Melchers M, Isik G, Menis S, Huang PS, et al. (2011) A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses. J Biol Chem 286: 22250-22261 M111.229625 [pii];10.1074/jbc.M111.229625 [doi].
43. Denecker G, Vandenabeele P, Grooten J, Penning LC, Declercq W, et al. (1997) Differential role of calcium in tumour necrosis factor-mediated apoptosis and secretion of granulocyte-macrophage colony-stimulating factor in a T cell hybridoma. Cytokine 9: 631-638 S1043-4666(97)90218-0 [pii];10.1006/cyto.1997.0218 [doi].
44. Just U, Friel J, Heberlein C, Tamura T, Baccarini M, et al. (1993) Upregulation of lineage specific receptors and ligands in multipotential progenitor cells is part of an endogenous program of differentiation. Growth Factors 9: 291-300.
45. Klein B, Le Bousse-Kerdiles C, Smadja-Joffe F, Pragnell I, Ostertag W, et al. (1982) A study of added GM-CSF independent granulocyte and macrophage precursors in mouse spleen infected with myeloproliferative sarcoma virus (MPSV). Exp Hematol 10: 373-382.
46. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, et al. (2004) Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A 101: 3903-3908 10.1073/pnas.0307348101 [doi];0307348101 [pii].
47. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, et al. (2005) TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 201: 35-39 jem.20032000 [pii];10.1084/jem.20032000 [doi].
48. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199: 91-98 10.1084/jem.20031330 [doi];199/1/91 [pii].
49. Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, et al. (2012) Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol 86: 2488-2500 JVI.06259-11 [pii];10.1128/JVI.06259-11 [doi].
50. Hill EE, Morea V, Chothia C (2002) Sequence conservation in families whose members have little or no sequence similarity: the four-helical cytokines and cytochromes. J Mol Biol 322: 205-233. S0022283602006538 [pii].
51. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, et al. (2005) IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 175: 7867-7879. 175/12/7867 [pii].
52. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, et al. (2004) Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 173: 5361-5371. 173/9/5361 [pii].
53. Eto D, Lao C, DiToro D, Barnett B, Escobar TC, et al. (2011) IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS One 6: e17739 10.1371/journal.pone.0017739 [doi].
54. Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, et al. (2004) T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol 173: 68-78.
55. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, et al. (2007) IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 178: 2827-2834. 178/5/2827 [pii].
56. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, et al. (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63 10.1038/35040504 [doi].
57. McHeyzer-Williams LJ, Pelletier N, Mark L, Fazilleau N, McHeyzer-Williams MG, (2009) Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol 21: 266-273 S0952-7915(09)00090-9 [pii];10.1016/j.coi.2009.05.010 [doi].
58. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG, (2009) Follicular helper T cells: lineage and location. Immunity 30: 324-335 S1074-7613(09)00114-9 [pii];10.1016/j.immuni.2009.03.003 [doi].
59. Thorbecke GJ, Amin AR, Tsiagbe VK, (1994) Biology of germinal centers in lymphoid tissue. FASEB J 8: 832-840.
60. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, et al. (2007) An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 13: 3630-3636 13/12/3630 [pii];10.1158/1078-0432.CCR-07-0410 [doi].
61. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, et al. (2005) Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 201: 139-148 jem.20041057 [pii];10.1084/jem.20041057 [doi].
62. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, et al. (2008) Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 26: 2034-2039 JCO.2007.14.5193 [pii];10.1200/JCO.2007.14.5193 [doi].
63. Bondensgaard K, Breinholt J, Madsen D, Omkvist DH, Kang L, et al. (2007) The existence of multiple conformers of interleukin-21 directs engineering of a superpotent analogue. J Biol Chem 282: 23326-23336 M701313200 [pii];10.1074/jbc.M701313200 [doi].
64. Kang L, Bondensgaard K, Li T, Hartmann R, Hjorth SA, (2010) Rational design of interleukin-21 antagonist through selective elimination of the gammaC binding epitope. J Biol Chem 285: 12223-12231 M110.101444 [pii];10.1074/jbc.M110.101444 [doi].
65. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, et al. (2002) Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 76: 2606-2616.
66. Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, et al. (2010) Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 401: 236-247 S0042-6822(10)00128-5 [pii];10.1016/j.virol.2010.02.019 [doi].
67. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, et al. (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76: 8875-8889.
68. Bontjer I, Land A, Eggink D, Verkade E, Tuin K, et al. (2009) Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol 83: 368-383 JVI.01404-08 [pii];10.1128/JVI.01404-08 [doi].
69. Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, et al. (2011) A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology 8: 48 1742-4690-8-48 [pii];10.1186/1742-4690-8-48 [doi].
70. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737 nature05580 [pii];10.1038/nature05580 [doi].
71. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S, (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109-113 nature07159 [pii];10.1038/nature07159 [doi].
72. He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, et al. (2006) HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 176: 3931-3941. 176/7/3931 [pii].
73. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, et al. (2010) B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 207: 155-171 jem.20091706 [pii];10.1084/jem.20091706 [doi].
74. Linterman MA, Beaton L, Yu D, Ramiscal RR, Srivastava M, et al. (2010) IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med 207: 353-363 jem.20091738 [pii];10.1084/jem.20091738 [doi].
75. Zotos D, Coquet JM, Zhang Y, Light A, D'Costa K, et al. (2010) IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med 207: 365-378 jem.20091777 [pii];10.1084/jem.20091777 [doi].
76. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193 jem.20101352 [pii];10.1084/jem.20101352 [doi].
77. Julien JP, Lee JH, Cupo A, Murin CD, Derking R, et al. (2013) Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A. 1217537110 [pii];10.1073/pnas.1217537110 [doi].
78. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84: 8098-8110 JVI.00966-10 [pii];10.1128/JVI.00966-10 [doi].
79. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, et al. (2010) Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107: 11483-11488 1004600107 [pii];10.1073/pnas.1004600107 [doi].
80. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289 1178746 [pii];10.1126/science.1178746 [doi].
81. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420 nature11519 [pii];10.1038/nature11519 [doi].
82. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612 10.1002/jcc.20084 [doi].
83. Kuhlman B, O'Neill JW, Kim DE, Zhang KY, Baker D, (2001) Conversion of monomeric protein L to an obligate dimer by computational protein design. Proc Natl Acad Sci U S A 98: 10687-10691 10.1073/pnas.181354398 [doi];181354398 [pii].
84. Liu Y, Kuhlman B, (2006) RosettaDesign server for protein design. Nucleic Acids Res 34: W235-W238 34/suppl_2/W235 [pii];10.1093/nar/gkl163 [doi].
85. Cutalo JM, Deterding LJ, Tomer KB, (2004) Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. J Am Soc Mass Spectrom 15: 1545-1555 S1044-0305(04)00480-5 [pii];10.1016/j.jasms.2004.07.008 [doi].
86. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373-10382.
87. Zhu X, Borchers C, Bienstock RJ, Tomer KB (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39: 11194-11204. bi000432m [pii].
88. DeLano WL (2002) The PyMOL Molecular Graphics System.